Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection
AIM: To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load.
MATERIALS AND METHODS: The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions.
RESULTS: The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA <120 copies/ml was achieved in 95% of the patients in both treatment groups. A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 μl) of CD4+ lymphocyte count in patients who took darunavir (362.2 in μl) and in those who used atazanavir (285.1 in μl). In the patients who received darunavir, diarrhea, nausea, and headache were observed at the same frequency as in those who had atazanavir.
CONCLUSION: The use of the test agents used in the ARVT has shown their efficacy and good tolerability.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 86(2014), 11 vom: 01., Seite 29-33 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Moshkovich, G F [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 16.03.2015 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM246561467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246561467 | ||
| 003 | DE-627 | ||
| 005 | 20231224143329.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n0821.xml |
| 035 | |a (DE-627)NLM246561467 | ||
| 035 | |a (NLM)25715484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Moshkovich, G F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2015 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load | ||
| 520 | |a MATERIALS AND METHODS: The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions | ||
| 520 | |a RESULTS: The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA <120 copies/ml was achieved in 95% of the patients in both treatment groups. A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 μl) of CD4+ lymphocyte count in patients who took darunavir (362.2 in μl) and in those who used atazanavir (285.1 in μl). In the patients who received darunavir, diarrhea, nausea, and headache were observed at the same frequency as in those who had atazanavir | ||
| 520 | |a CONCLUSION: The use of the test agents used in the ARVT has shown their efficacy and good tolerability | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Atazanavir Sulfate |2 NLM | |
| 650 | 7 | |a 4MT4VIE29P |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Minaeva, S V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 86(2014), 11 vom: 01., Seite 29-33 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2014 |g number:11 |g day:01 |g pages:29-33 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2014 |e 11 |b 01 |h 29-33 | ||